Patents by Inventor Thomas H. Marsilje
Thomas H. Marsilje has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9440957Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.Type: GrantFiled: June 5, 2013Date of Patent: September 13, 2016Assignee: Novartis AGInventors: Gerald Lelais, Robert Epple, Thomas H. Marsilje, III, Pierre-Yves Michellys, Matthew McNeill, Yun Long, Wenshuo Lu, Bei Chen, Badry Bursulaya, Songchun Jiang
-
Publication number: 20150197505Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.Type: ApplicationFiled: June 5, 2013Publication date: July 16, 2015Applicant: IRM LLC, A Delaware Limited Liability CompanyInventors: Gerald Lelais, Robert Epple, Thomas H. Marsilje, III, Pierre-Yves Michellys, Matthew McNeill, Yun Long, Wenshuo Lu, Bei Chen, Badry Bursulaya Bursulaya, Songchun Jiang
-
Publication number: 20150152083Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.Type: ApplicationFiled: June 5, 2013Publication date: June 4, 2015Applicant: IRM LLC, A Delaware Limited Liability CompanyInventors: Gerald Lelais, Robert Epple, Pierre-Yves Michellys, Badry Bursulaya, Songchun Jiang, Thomas H. Marsilje III, Matthew MCneill
-
Publication number: 20150105390Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.Type: ApplicationFiled: December 17, 2014Publication date: April 16, 2015Applicant: IRM LLC, a Delaware Limited Liability CompanyInventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, III, Wenshuo Lu, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
-
Patent number: 8957081Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.Type: GrantFiled: September 11, 2012Date of Patent: February 17, 2015Assignee: IRM LLCInventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, III, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
-
Patent number: 8859574Abstract: The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK).Type: GrantFiled: July 23, 2013Date of Patent: October 14, 2014Assignee: IRM LLCInventors: Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Xiaohui He, Christian Cho-Hua Lee, Songchun Jiang, Kunyong Yang
-
Publication number: 20140209464Abstract: Among other things, for use in directional motion of chiral objects in a mixture, a field is applied across the chamber and is rotating relative to the chamber to cause rotation of the chiral objects. The rotation of the objects causes them to move directionally based on their chirality. The method applies to sugars, proteins, and peptides, among other things, and can be used in a wide variety of applications.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: Dynamic Connections, LLCInventors: Osman Kibar, Mirianas Chachisvilis, Eugene Tu, Thomas H. Marsilje
-
Patent number: 8698031Abstract: Among other things, for use in directional motion of chiral objects in a mixture, a field is applied across the chamber and is rotating relative to the chamber to cause rotation of the chiral objects. The rotation of the objects causes them to move directionally based on their chirality. The method applies to sugars, proteins, and peptides, among other things, and can be used in a wide variety of applications.Type: GrantFiled: June 19, 2008Date of Patent: April 15, 2014Assignee: Dynamic Connections, LLCInventors: Osman Kibar, Mirianas Chachisvilis, Eugene Tu, Thomas H. Marsilje
-
Publication number: 20130338152Abstract: The present invention provides a compound the invention, and its use as a IGF-1R inhibitor. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: March 8, 2012Publication date: December 19, 2013Applicants: IRM LLC, NOVARTIS AGInventors: Bei Chen, Robin Alec Fairhurst, Songchun Jiang, Wenshuo Lu, Thomas H. Marsilje, III, Clive McCarthy, Pierre-Yves Michellys, Stefan Stutz
-
Patent number: 8592432Abstract: The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-1R), and/or insulin receptor (InsR) or a combination thereof.Type: GrantFiled: April 3, 2009Date of Patent: November 26, 2013Inventors: Bei Chen, Tao Jiang, Thomas H. Marsilje, Pierre-Yves Michellys, Truc Ngoc Nguyen, Wei Pei, Baogen Wu, Zhaobo Gao, Yonghui Ge, Chen Huang, Yuncheng Li, Xuefeng Zhu
-
Publication number: 20130310361Abstract: The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK).Type: ApplicationFiled: July 23, 2013Publication date: November 21, 2013Inventors: Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Xiaohui He, Christian Cho-Hua Lee, Songchun Jiang, Kunyong Yang
-
Patent number: 8519129Abstract: The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).Type: GrantFiled: June 24, 2009Date of Patent: August 27, 2013Assignee: IRM LLCInventors: Thomas H. Marsilje, III, Wenshuo Lu, Bei Chen, Xiaohui He, Christian Cho-Hua Lee, Songchun Jiang, Kunyong Yang
-
Patent number: 8445505Abstract: The invention provides novel pyrimidine derivatives of formula (I) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).Type: GrantFiled: June 24, 2009Date of Patent: May 21, 2013Assignee: IRM LLCInventors: Thomas H. Marsilje, III, Wenshuo Lu, Bei Chen, Xiaohui He, Songchun Jiang, Kunyong Yang
-
Patent number: 8440681Abstract: The invention provides novel pyrimidine derivatives of formula (1) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase (ALK).Type: GrantFiled: August 27, 2008Date of Patent: May 14, 2013Assignee: IRM LLCInventors: Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Xiaohui He, Badry Bursulaya, Christian Cho-Hua Lee
-
Patent number: 8399450Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.Type: GrantFiled: June 29, 2011Date of Patent: March 19, 2013Assignee: IRM LLCInventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
-
Patent number: 8377921Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.Type: GrantFiled: June 29, 2011Date of Patent: February 19, 2013Assignee: IRM LLCInventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Bei Chen, Tetsuo Uno
-
Patent number: 8372858Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.Type: GrantFiled: March 15, 2011Date of Patent: February 12, 2013Assignee: IRM LLCInventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
-
Publication number: 20130005748Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Applicant: IRM LLCInventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
-
Publication number: 20120289501Abstract: The invention relates to new derivatives of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a proliferative disease.Type: ApplicationFiled: November 23, 2010Publication date: November 15, 2012Applicant: NOVARTIS AGInventors: Bei Chen, Robin Alec Fairhurst, Andreas Floersheimer, Pascal Furet, Songchun Jiang, Wenshuo Lu, Thomas H. Marsilje, III, Andrea Vaupel
-
Publication number: 20120165310Abstract: The invention relates to compounds of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; such compounds as a medicament; such compounds for the treatment of a proliferative disease.Type: ApplicationFiled: September 10, 2010Publication date: June 28, 2012Applicant: NOVARTIS AGInventors: Bei Chen, Robin Alec Fairhurst, Andreas Floersheimer, Pascal Furet, Vito Guagnano, Jiang Songchun, Wenshuo Lu, Thomas H. Marsilje, III, Clive McCarthy, Pierre-Yves Michellys, Frederic Stauffer, Stefan Stutz, Andrea Vaupel